Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?

Malek, Alexandre E; Dagher, Hiba; Hachem, Ray; Chaftari, Anne M; Raad, Issam I

Malek, Alexandre E; Dagher, Hiba; Hachem, Ray; Chaftari, Anne M; Raad, Issam I.

Malek AE; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dagher H; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hachem R; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chaftari AM; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Raad II; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

J Med Virol ; 93(7): 4083-4084, 2021 Jul.

Article in English | MEDLINE | ID: covidwho-1118164

Subject(s)

COVID-19 Vaccines/administration & dosage; COVID-19/immunology; COVID-19/prevention & control; Vaccines, Synthetic/administration & dosage; 2019-nCoV Vaccine mRNA-1273; Adult; BNT162 Vaccine; Humans; Immunity; Immunization Schedule; Reinfection/prevention & control

Keywords

COVID-19; mRNA vaccine; pandemic; single shot; survivors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adult / Humans Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26915

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google